“Digital biomarkers: Do they hold promise for better neuropsychiatric disease detection?”

Nov. 14, 2018 from 3:30 to 4:20 p.m. — Health Sciences Building, Room K-069

Reza Hosseini Ghomi, Director of the DigiPsych Lab and Chief Medical Officer for NeuroLex Laboratories

[Watch a recording of this seminar on YouTube.]

Abstract

For this talk I would like to review the field of digital biomarkers and provide some background and context for our work. Specifically, what are digital biomarkers and how are they useful? I will show some results of our early work using recorded voice samples, accelerometer data, neuroimaging measures, and several other objective and subjective measures from patients with Parkinson’s, Depression, Schizophrenia, and from the Framingham Heart Study’s cognitive aging cohort. We will touch on the shifting paradigm of research to complete work in this area of big data and what we can do differently moving forward to offer novel insights.

Bio

A photo of Reza Hosseini Ghomi

Reza’s passion lies at the intersection of neuropsychiatry, technology, and education. He is most interested in bringing significant and measurable improvement to the screening, diagnosis, and treatment of neuropsychiatric illness through the advancement of technology, and empowerment through collaboration.

To that end, when he is not practicing neuropsychiatry, he is director of the DigiPsych Lab and chief medical officer for NeuroLex Laboratories where his research and development work focuses on the exciting new field of voice diagnostics – using a brief recording of voice to screen, diagnose, and track a wide range of illnesses in an ultra-rapid, cost-effective, accurate, and accessible way.

He draws on his previous experience as an engineer – developing imaging technology at Massachusetts General Hospital and an electronic health record for VecnaCares. He is also a founding partner of Stanford Brainstorm, the first behavioral health innovation and entrepreneurship laboratory.

He holds a BS in electrical and computer engineering from Rensselaer Polytechnic Institute, an MSE in biomedical and electrical engineering from Johns Hopkins University, and an MD from University of Massachusetts Medical School, and is now completing and transitioning from the University of Washington’s psychiatry residency to their neurology movement disorders fellowship to focus on neurodegenerative disease.

This seminar is presented in partnership with the UW Institute for Neuroengineering.